Levothyroxine Sodium Tablets Recalled for Out-of-Specification Potency
Mylan Institutional is recalling Levothyroxine Sodium Tablets 150 mcg due to out-of-specification potency. The medication tested higher than specified, affecting 347 cartons distributed nationwide (Lot 3116074, expires 09/30/2025).
What this means for you
Real risk of harm even if no illness or injury has been reported yet. Stop using the product and follow the agency's guidance.
Our severity reasoning: FDA Class II drug recall with out-of-specification potency identified. No reported illnesses or hospitalizations. Qualifies as a risk-of-harm product where injury has not yet been reported, per rubric Score 3 criteria.
Plain-English summary
Mylan Institutional, Inc. is recalling Levothyroxine Sodium Tablets, USP, 150 mcg (0.15 mg), in 100 Unit Dose Blister Cards format. The recall affects 347 cartons distributed nationwide.
The recall was initiated due to out-of-specification potency results. Testing showed the tablets contained higher potency than specified. The affected lot is 3116074, with an expiration date of September 30, 2025. The product was manufactured in India.
Patients taking this medication should contact their pharmacy or healthcare provider regarding this recall. Patients should not discontinue levothyroxine, a critical thyroid hormone, without guidance from their healthcare provider.
The recalled product
- Product
- LEVOTHYROXINE SODIUM (LEVOTHYROXINE SODIUM)
- Brand
- LEVOTHYROXINE SODIUM
- Manufacturer
- Mylan Institutional, Inc.
- Category
- Drug
- Affected units
- 347
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot 3116074
- Exp. 09/30/2025
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 2 recalled by Mylan Institutional, Inc. under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 2 products in this recall →Related recalls
Same brand · LEVOTHYROXINE SODIUM
- HighAccord Healthcare Recalls Subpotent Levothyroxine Sodium Tablets
FDA (Drugs) · 2026-09-02
- ModerateAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- SevereAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
- HighAccord Recalls Subpotent Levothyroxine Sodium Tablets Nationwide
FDA (Drugs) · 2026-09-02
Same manufacturer · Mylan Institutional, Inc.
See all →- HighFDA Recalls Super-Potent Levothyroxine Sodium Tablets Due to Potency Deviation
FDA (Drugs) · 2025-03-26
- HighFDA Recalls Levothyroxine Sodium Tablets for Potency Variation
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium 100 mcg Tablets Recalled for Potency Deviations Nationwide
FDA (Drugs) · 2024-12-18
- HighLevothyroxine sodium tablets recalled for potency variance
FDA (Drugs) · 2024-12-18
- HighLevothyroxine Sodium Tablets Recalled for Subpotent and Superpotent Content
FDA (Drugs) · 2024-12-18
Same hazard · out of specification
See all →- ModerateDabigatran Etexilate Capsules Recalled Over Impurity Test Failure
FDA (Drugs) · 2026-07-29
- ModerateAquacel Ag Surgical SP Surgical Dressing Recalled for Out-of-Specification Thickness
FDA (Devices) · 2026-07-15
- SevereGlucagon Emergency Kit Recalled for Manufacturing Process Deviation
FDA (Drugs) · 2026-07-08
- HighMedline pre-connected urethral catheterization trays fail performance specifications
FDA (Devices) · 2026-06-24
- HighMedline 15 Fr urethral catheterization trays fail performance specifications
FDA (Devices) · 2026-06-24